CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Devonian Health Group Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Devonian Health Group Inc
360 rue des Entrepreneurs
Phone: (514) 248-7509p:514 248-7509 MONTMAGNY, QC  G5V 4T1  Canada Ticker: GSDGSD
Business Summary
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company is focused on developing prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases, including but not limited to ulcerative colitis and atopic dermatitis. It is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health conditions related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., is focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
4/30/20247/31/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Secretary RichardProvencher 54
President, Chief Executive Officer, Director BenoitChotard
Chief Financial Officer, Vice President, Director NormandDrolet 57
Director CynthiaMailloux 45
Director OctavioSoares 61

Business Names
Business Name
GSD
OLE.P

General Information
Number of Employees: 6 (As of 7/31/2023)
Outstanding Shares: 148,222,532 (As of 4/30/2024)
Stock Exchange: CVE
Fax Number: (450) 937-6696


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024